+ All Categories
Home > Documents > Nephrotic Syndrome 2016

Nephrotic Syndrome 2016

Date post: 28-Feb-2018
Category:
Upload: alaa
View: 217 times
Download: 0 times
Share this document with a friend

of 45

Transcript
  • 7/25/2019 Nephrotic Syndrome 2016

    1/45

    Nephrotic Syndrome

    Abdulrahman Mashi

  • 7/25/2019 Nephrotic Syndrome 2016

    2/45

    Nephrotic Syndrome

    Nephrotic-range proteinuria : urine proteinexcretion of >3.5 g!" h or a urine protein-

    creatinine ratio of >35## mgg in a $spot$morning urine sample

    %ypoalbuminemia &serum albumin' 3 gd().

    *demaHyperlipidemia

  • 7/25/2019 Nephrotic Syndrome 2016

    3/45

    +athogenesis

    Underfll

    Model

    Overfll

    Model

    Permeability of glom.cap.memb. Proteinuria

    Intravascular vol

    ADHRenal perfusion

    pressure

    Water

    Reabsorptn

    InCollectingducts

    Actv. reinin

    Ang. ald. sys

    Tubular reabsorp.

    Of a

    Hypoalbuminemia

    Hepatic protein synt!esis

    Plasma oncotic

    pressure

    HyperlipidemiaTransudation of fluid

    from intravascular

    comp. To interstial

    space

    "dema

  • 7/25/2019 Nephrotic Syndrome 2016

    4/45

    *le,ated lipids occur from a combinationof

    increased hepatic apolipoprotein

    synthesis in response to a lo plasmaoncotic pressure

    decreased acti,ity of ey en/ymes suchas lipoprotein lipase and lecithin-cholesterol acyltransferase.

  • 7/25/2019 Nephrotic Syndrome 2016

    5/45

    Nephrotic Syndrome

    NephroticSyndrom

    e

    +rimary&0diopathic)

    Secondary

  • 7/25/2019 Nephrotic Syndrome 2016

    6/45

    Nephrotic Syndrome

    Primary (idiopathic)Minimal change disease &M12)

    Membranous nephropathy &MN)

    ocal segmental glomerulosclerosis &S4S).

    Mesangiocapillary &Membranoproliferati,e) 4N&M14N M+4N)

    ibrillary glomerulopathy : may be assocaited emalignacy

    Immunotactoid glomerulopathy : May beassociated with chronic lymphocytic leukemia or Bcelllymphomas

  • 7/25/2019 Nephrotic Syndrome 2016

    7/45

    Nephrotic Syndrome

    Secondary

    2iabetes &the most common)

    0nfections

    2rugs

    Autoimmune diseases

    Amyloidosis

    Monoclonal immunoglobulin depositiondisease

  • 7/25/2019 Nephrotic Syndrome 2016

    8/45

    Nephrotic Syndrome

    Important pointsMinimal change glomerulopathyis the most common cause of thenephrotic syndrome in children

    Membranous glomerulopathy and !S"S are the most common

    causes of idiopathic nephrotic syndrome in adults.

    Membranous glomerulopathy is the most common orldide

    !S"Sis the most common in S and no increasing to be the mostcommon orldide

    !S"Sis the most common cause in blac personsMembranous glomerulopathyis the most common cause in hitepersons

    Membranous glomerulopathy has the highest predilection forrenal #ein thrombosis among all causes of the nephrotic syndrome

  • 7/25/2019 Nephrotic Syndrome 2016

    9/45

    *,aluation

  • 7/25/2019 Nephrotic Syndrome 2016

    10/45

    6reatment

    4eneral measures: *le,ated lipid le,els are typically

    treated ith statin medications

    +rophylactic anticoagulation : 0n any type of Nephrotic if albumin le,el

    7!.# gd( &!# g() ith lo bleeding risregardless of cause.

    0n patients ith membranousglomerulopathy ith lo ris for bleedinghas been if albumin 7!.8 gd( &!8 g().

  • 7/25/2019 Nephrotic Syndrome 2016

    11/45

    6reatment

    4eneral measures: *dema is treated ith a lo salt diet

    and loop diuretics &alone or in

    combination ith a thia/ide andpotassium-sparing diuretics).

    A1* and A; to reduce proteinurea

    Maintain good nutrition6reatment of underlying cause

  • 7/25/2019 Nephrotic Syndrome 2016

    12/45

    1omplications

  • 7/25/2019 Nephrotic Syndrome 2016

    13/45

  • 7/25/2019 Nephrotic Syndrome 2016

    14/45

  • 7/25/2019 Nephrotic Syndrome 2016

    15/45

    S4S

    1auses: 0diopathic : Some cases of idiopathic S4S are thought to

    be related to a circulating plasma factor because a signi

  • 7/25/2019 Nephrotic Syndrome 2016

    16/45

    S4S

    !i#e subtypes

    not otherise speci

  • 7/25/2019 Nephrotic Syndrome 2016

    17/45

    S4S

    linical Mani%estations :

    *ither asymptomatic proteinuria or edema.

    More than to thirds of patients are fully

    nephrotic at presentation Subnephrotic proteinuria may occur

    especially ith secondary S4S fromhyper

  • 7/25/2019 Nephrotic Syndrome 2016

    18/45

    S4S

    iagnosis

    6he hallmar of S4S is the presence ofsegmental scars in some glomeruli.

    *lectron microscopy shos ,isceralepithelial cell %oot process e*acement

    no immune deposits+

  • 7/25/2019 Nephrotic Syndrome 2016

    19/45

    -reatment and Prognosis

    0n idiopathic S4S only a minority of patients

    experience a spontaneous remission.

    -here%ore& treatment is indicated in mostpatients+

    6herapy is usually ith glucocorticoids or calcineurininhibitors both at the time of initial presentation andfor relapsing disease.

    A complete or partial remission may be seen in up to"#B to C#B of patients using these treatments.

    S4S recurs in the transplanted idney in 3#B or more

    of cases.

  • 7/25/2019 Nephrotic Syndrome 2016

    20/45

    0n secondary S4S caused by infection ordrugs treatment of the infection or remo,alof the oDending agent may halt progressionof the disease and impro,e symptoms.

    0n obese patients ith liely secondaryS4S eight loss is sometimes associatedith a drop in proteinuria as is the use ofA1* inhibitors or angiotensin receptorblocers &A;s) and is the preferred initialtherapy.

  • 7/25/2019 Nephrotic Syndrome 2016

    21/45

    Membranous 4lomerulopathy

    Primary or secondary

    Primary %orm &most commonorldide): antiphospholipaseA!receptor autoantibodies can be

    found in E5B of cases lead to

    acti,ation of complement anddamage the 4;M.

  • 7/25/2019 Nephrotic Syndrome 2016

    22/45

    Membranous 4lomerulopathy

    May be associated with or secondary to:

    S(*

    0nfections: hepatitis ; and 1 ,irus infectionsF syphilisF

    malaria Medication exposure: penicillamineF NSA02sF 6N-G

    inhibitorsF tiopronin

    Mercury or gold exposure

    Malignancies: Solid organ Malignancy &bladderbreast colon lung pancreas prostate stomachcarcinoma)F carcinoidF sarcomasF lymphomasFleuemias

    6hyroid disease

  • 7/25/2019 Nephrotic Syndrome 2016

    23/45

    1linical Manifestations

    (ie other causes of the nephroticsyndrome &edema hypertensionmicrohematuria) but the propensity to

    thromboembolic e,ents &particularlyrenal ,ein thrombosis) is much higher.

    Secondary causes should be soughtparticularly occult malignancy in olderpatients.

  • 7/25/2019 Nephrotic Syndrome 2016

    24/45

    Membranous4lomerulopathy

    iagnosis

    (ight microscopy shos glomerular capillaryloops that often appear thicened ithout

    any proliferati,e lesions.0mmuno@uorescence and electronmicroscopy sho subepithelial immunedense deposits.

    .here a#ailable& P/012 antibodies

    should be measured+

  • 7/25/2019 Nephrotic Syndrome 2016

    25/45

    6reatment

    p to one third of patients ith idiopathic M4 remitspontaneously in C to H! months.

    1onser,ati,e management is appropriate during

    this period.

    0n patients ith idiopathic M4 who ha#epersistent disease a%ter 3 to 41 months or

    who ha#e worsening kidney %unction or athromboembolic e#ent&regimens containingalternating glucocorticoids ith cyclophosphamideor calcineurin inhibitors &cyclosporine or tacrolimus)may be used.

  • 7/25/2019 Nephrotic Syndrome 2016

    26/45

    6reatment

    Ither options for relapsing or refractorydisease include mycophenolate mofetil

    adrenocorticotropic hormone and theantiJ;-cell antibody rituximab.

    or secondary causes of M4 treat theunderlying cause lie treatment ofhepatitis ; ,irus infection ith anti,iralagents

  • 7/25/2019 Nephrotic Syndrome 2016

    27/45

  • 7/25/2019 Nephrotic Syndrome 2016

    28/45

  • 7/25/2019 Nephrotic Syndrome 2016

    29/45

    Minimal 1hange 4lomerulopathy

    Primary %orm &0diopathic)

    secondary : Medications &such as NSA02s lithium

    pamidronate rifampin and the interferons) Malignancies &such as %odgin

    lymphoma other lymphoproliferati,edisorders and thymoma)

    0nfections: 0nfectious Mononucleosis and 6;

  • 7/25/2019 Nephrotic Syndrome 2016

    30/45

    linical Mani%estations

    +atients ith M14 typically presentith acute onset of edema andeight gain due to @uid retention.

    rine protein le,els tend to besigni

  • 7/25/2019 Nephrotic Syndrome 2016

    31/45

    M12

    iagnosis

    Normal glomeruli on both light andimmuno@uorescence microscopy.

    6he tubules may sho lipid accumulation.

    6n electron microscopy& the "BM isnormal with e'tensi#e e*acement o%

    #isceral epithelial %oot processes+

  • 7/25/2019 Nephrotic Syndrome 2016

    32/45

    6reatment

    +atients typically respond to glucocorticoids &Hmggd or!mgg e,ery other day )ithin 8 to HC ees.

    1omplete remission achie,ed in around E# B

    elapse is common and in up to "#B of patients thecourse of M14 is one of remission folloed by relapse.

    or freKuently relapsing or glucocorticoid-dependent

    disease treatment options include cyclophosphamidecalcineurin inhibitors &tacrolimus or cyclosporine)mycophenolate mofetil and rituximab.

  • 7/25/2019 Nephrotic Syndrome 2016

    33/45

  • 7/25/2019 Nephrotic Syndrome 2016

    34/45

    2iabetic Nephropathy

    2iabetic nephropathy &2N) is theleading cause of *SL2 in the nitedStates

    6he strongest clinical indicator forprogressi,e idney disease is the

    le,el of urine albumin.

  • 7/25/2019 Nephrotic Syndrome 2016

    35/45

    2isk %actors %or de#eloping N

    older age

    race &American 0ndian Mexican American

    and blac)poor glycemic control

    hypertension

    cigarette smoingfamily history of idney disease

  • 7/25/2019 Nephrotic Syndrome 2016

    36/45

  • 7/25/2019 Nephrotic Syndrome 2016

    37/45

    linical Mani%estations

    Moderately increased albuminuria &formerly nonas microalbuminuria) de

  • 7/25/2019 Nephrotic Syndrome 2016

    38/45

    iagnosis

    Annual testing for albuminuria should begin at

    the time of diagnosis in type ! diabetes and 5years after diagnosis in type H diabetes.

    Lidney biopsy is not indicated unless there isa suspicion of another glomerular disease.

    In electron microscopy the 4;M is normalith extensi,e eDacement of ,isceralepithelial foot processes.

    Moderately increased albuminuria de

  • 7/25/2019 Nephrotic Syndrome 2016

    39/45

    Indications %or kidney biopsy

    acute onset of the nephrotic syndrome

  • 7/25/2019 Nephrotic Syndrome 2016

    40/45

    +athology

    2N aDects e,ery compartment of the idney.

    0n the glomerulus there is e'pansion o% themesangium and thickening o% the basementmembrane folloed by focal &nodular) sclerosis&the Limmelstiel-ilson lesion) then globalsclerosis of the glomerulus.

    0nterstitial

  • 7/25/2019 Nephrotic Syndrome 2016

    41/45

    6reatment

    Achie,ing targets of glycemic control&hemoglobin AHc'EB) and blood

    pressure &'H"## mm %g.

    0n patients ho ha,e diabetes ithmoderately increased albuminuria or

    se,erely increased albuminuria A1*inhibitors or A;s ha,e been shon toslo progression.

  • 7/25/2019 Nephrotic Syndrome 2016

    42/45

    ead about

    M+4N

    Amylodosis

    Multiple Myloma

    %0 associated nephropathy

    %epatitis ; associated idney disease

  • 7/25/2019 Nephrotic Syndrome 2016

    43/45

  • 7/25/2019 Nephrotic Syndrome 2016

    44/45

    eferences

  • 7/25/2019 Nephrotic Syndrome 2016

    45/45


Recommended